BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 26227068)

  • 41. [Low persistence of simvastatin and ezetimibe fixed combination in the lipid lowering therapy].
    Simonyi G; Ferenci T
    Orv Hetil; 2015 Jan; 156(4):141-5. PubMed ID: 25597318
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impact of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines on the prescription of high-intensity statins in patients hospitalized for acute coronary syndrome or stroke.
    Valentino M; Al Danaf J; Panakos A; Ragupathi L; Duffy D; Whellan D
    Am Heart J; 2016 Nov; 181():130-136. PubMed ID: 27823684
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction.
    Toth PP; Ballantyne CM; Davidson MH; Tomassini JE; Ramey DR; Neff D; Tershakovec AM; Hu XH; Tunceli K
    J Clin Lipidol; 2012; 6(2):180-91. PubMed ID: 22385552
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacodynamic interaction between ezetimibe and rosuvastatin.
    Kosoglou T; Statkevich P; Yang B; Suresh R; Zhu Y; Boutros T; Maxwell SE; Tiessen R; Cutler DL
    Curr Med Res Opin; 2004 Aug; 20(8):1185-95. PubMed ID: 15324521
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study.
    Lin Wu FL; Wang J; Ho W; Chou CH; Wu YJ; Choo DW; Wang YW; Chen PY; Chien KL; Lin ZF
    Int J Cardiol; 2017 Apr; 233():43-51. PubMed ID: 28190615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis.
    Zhao Z; Du S; Shen S; Luo P; Ding S; Wang G; Wang L
    Medicine (Baltimore); 2019 Feb; 98(6):e14400. PubMed ID: 30732185
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical outcome of statin plus ezetimibe versus high-intensity statin therapy in patients with acute myocardial infarction propensity-score matching analysis.
    Ji MS; Jeong MH; Ahn YK; Kim SH; Kim YJ; Chae SC; Hong TJ; Seong IW; Chae JK; Kim CJ; Cho MC; Rha SW; Bae JH; Seung KB; Park SJ;
    Int J Cardiol; 2016 Dec; 225():50-59. PubMed ID: 27710803
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared to rosuvastatin 10 mg in high-risk patients with and without type 2 diabetes mellitus inadequately controlled despite prior statin monotherapy.
    Vaverkova H; Farnier M; Averna M; Missault L; Viigimaa M; Dong Q; Shah A; Johnson-Levonas AO; Brudi P
    Cardiovasc Ther; 2012 Apr; 30(2):61-74. PubMed ID: 20626402
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
    Bittner V; Deng L; Rosenson RS; Taylor B; Glasser SP; Kent ST; Farkouh ME; Muntner P
    J Am Coll Cardiol; 2015 Oct; 66(17):1864-72. PubMed ID: 26493657
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Management of Severe and Moderate Hypercholesterolemia in Young Women and Men.
    Newton SL; Hoffmann AP; Yu Z; Haidermota S; Natarajan P; Honigberg MC
    JAMA Cardiol; 2022 Feb; 7(2):227-230. PubMed ID: 34780599
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
    Robinson JG; Nedergaard BS; Rogers WJ; Fialkow J; Neutel JM; Ramstad D; Somaratne R; Legg JC; Nelson P; Scott R; Wasserman SM; Weiss R;
    JAMA; 2014 May; 311(18):1870-82. PubMed ID: 24825642
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for 'pleiotropic' functions of statin therapy.
    Fichtlscherer S; Schmidt-Lucke C; Bojunga S; Rössig L; Heeschen C; Dimmeler S; Zeiher AM
    Eur Heart J; 2006 May; 27(10):1182-90. PubMed ID: 16621868
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Use of ezetimibe in the United States and Canada.
    Jackevicius CA; Tu JV; Ross JS; Ko DT; Krumholz HM
    N Engl J Med; 2008 Apr; 358(17):1819-28. PubMed ID: 18375999
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Statin and ezetimibe combination therapy in cardiovascular disease.
    Dembowski E; Davidson MH
    Curr Opin Endocrinol Diabetes Obes; 2009 Apr; 16(2):183-8. PubMed ID: 19262375
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid-lowering drug prescriptions in a group of Colombian patients.
    Gaviria-Mendoza A; Machado-Duque ME; Machado-Alba JE
    Biomedica; 2019 Dec; 39(4):759-768. PubMed ID: 31860186
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Adherence to Lipid-Lowering Treatment by Single-Pill Combination of Statin and Ezetimibe.
    Rea F; Savaré L; Corrao G; Mancia G
    Adv Ther; 2021 Oct; 38(10):5270-5285. PubMed ID: 34480293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of a Combined Measure of Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other Cardiovascular Risk Factors Treated With Statins and/or Ezetimibe.
    Khunti K; Danese MD; Kutikova L; Catterick D; Sorio-Vilela F; Gleeson M; Kondapally Seshasai SR; Brownrigg J; Ray KK
    JAMA Netw Open; 2018 Dec; 1(8):e185554. PubMed ID: 30646277
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Type of preexisting lipid therapy predicts LDL-C response to ezetimibe.
    Meyers CD; Moon YS; Ghanem H; Wong ND
    Ann Pharmacother; 2006 May; 40(5):818-23. PubMed ID: 16638916
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease.
    Gupta M; Szmitko PE; Tsigoulis M; Braga MF; Kajil M; Herjikaka S; Quan A; Teoh H; Verma S
    J Cardiovasc Pharmacol; 2010 Sep; 56(3):241-5. PubMed ID: 20505518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.